<DOC>
	<DOCNO>NCT01039610</DOCNO>
	<brief_summary>GSK945237 belong Bacterial Type II Topoisomerase Inhibitor ( BTI ) class antibiotic . GSK945237 demonstrate vitro vivo activity Gram positive [ include methicillin resistant Staphylococcus aureus ( MRSA ) ] Gram-negative pathogen associate respiratory tract , skin soft tissue infection include isolates resistant exist class antimicrobial . This study conduct four ( 4 ) part , single oral dose explore Part A ( 2400 mg ) repeat oral dos ( b.i.d . q.d . ) explore Part B . Parts C D optional evaluation repeat oral dos linezolid comparative evaluation effect GSK945237 moxifloxacin , respectively . Parts A B single-blind , randomize , placebo-controlled , dose-rising ( Part B ) study healthy subject evaluate safety , tolerability pharmacokinetics GSK945237 . The propose dos range 400 mg 2400 mg. Part C single-blind , randomize , placebo-controlled repeat dose evaluation 600 mg ( b.i.d . ) linezolid . Part D single-blind , randomize , placebo-controlled , two period crossover study . The propose dos Part D 1200 mg GSK945237 400 mg moxifloxacin .</brief_summary>
	<brief_title>A Single Center Four Part Study Healthy Adult Subjects Evaluate : Safety , Tolerability Pharmacokinetics Single Oral Dose Repeat Escalating Oral Doses GSK945237 ; Effect Linezolid Hematology Safety Parameters ; Effects GSK945237 Moxifloxacin QTc .</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . A subject nonclinically significant abnormality laboratory parameter outside reference range may include investigator considers find introduce additional risk factor interfere study procedure data interpretation . Male female 18 60 year age . A female subject eligible participate : Nonchildbearing potential define premenopausal female document bilateral tubal ligation , hysterectomy , bilateral oophorectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication least 90 day postlast dose . Body weight great 50 kg BMI within range 19 32 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . Any clinically significant central nervous system ( e.g. , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition history condition , opinion investigator may place subject unacceptable risk participant trial may interfere absorption , distribution , metabolism excretion drug . Any preexisting retinal condition find baseline examination , opinion investigator , may place subject unacceptable risk participant trial may interfere interpretation ophthalmologic safety result conduct trial . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit average daily intake great 3 unit ( male ) , defined average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin recommend daily intake herbal dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication , use St. John 's Wort within 14 day prior first dose study medication . By exception , volunteer may take acetaminophen ( &lt; equal 2 grams/day ) ibuprofen ( 1600 mg/day ) 48 hour prior first dose study medication . However , investigator study team review medication use case case basis determine use would compromise subject safety interfere study procedure data interpretation . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . The subject donate blood within 2 month prior dose and/or donate plasma within 1 week prior dose . An unwillingness male subject abstain sexual intercourse pregnant lactate woman , unwillingness male subject use condom spermicide , addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation , engage sexual intercourse female partner could become pregnant . This criterion must follow time study medication administration 90 day study medication administration . Lactating female . Unwillingness inability follow procedure outline protocol . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . For Part C Part D : Contraindications use linezolid moxifloxacin , respectively per package insert [ Avelox Product Information , 2008 ; Zyvox Product Information , 2008 ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>single dose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK945237</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>antibiotic</keyword>
	<keyword>linezolid</keyword>
	<keyword>QTc</keyword>
	<keyword>bacterial type II topoisomerase Inhibitors ( BTI )</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>repeat dose</keyword>
</DOC>